Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatocellular carcinoma.

G A Macdonald1

  • 1Royal Brisbane Hospital, Herston, Queensland, Australia.

Current Opinion in Gastroenterology
|October 7, 2006
PubMed
Summary
This summary is machine-generated.

Hepatitis C infection can directly cause liver cancer (hepatocellular carcinoma). Research explores risk factors like irregular regeneration and potential treatments such as interferon, though more randomized studies are needed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of beta-blockers on cardiopulmonary exercise testing in patients with advanced liver disease.

Alimentary pharmacology & therapeutics·2017
Same author

Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability.

Alimentary pharmacology & therapeutics·2016
Same author

Cooked sausage batter cohesiveness as affected by sarcoplasmic proteins.

Meat science·2011
Same author

Leptin and the risk of Barrett's oesophagus.

Gut·2008
Same author

Living with chronic hepatitis C means 'you just haven't got a normal life any more'.

Chronic illness·2006
Same author

Hepatocellular carcinoma.

Current opinion in gastroenterology·2006
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
See all related articles

Area of Science:

  • Hepatology
  • Oncology
  • Virology

Background:

  • Hepatitis C infection is a known risk factor for hepatocellular carcinoma (HCC).
  • Transgenic mouse models expressing hepatitis C core protein develop HCC without significant inflammation, suggesting a direct oncogenic role.
  • New insights into HCC development and risk stratification are emerging.

Purpose of the Study:

  • To review recent findings on the association between Hepatitis C virus (HCV) infection and hepatocellular carcinoma.
  • To explore potential pre-malignant lesions and risk factors for HCC development in HCV patients.
  • To evaluate the efficacy of various therapeutic interventions for HCC.

Main Methods:

  • Review of studies investigating transgenic mice expressing HCV core protein.

Related Experiment Videos

  • Analysis of research on specific liver lesions (irregular regeneration, large cell dysplasia) and their association with HCC risk.
  • Examination of epidemiological data on oral contraceptives and HCC.
  • Evaluation of clinical trial results for treatments like tamoxifen and octreotide.
  • Assessment of the impact of interferon therapy on HCC risk.

    • Main Results:

    • HCV core protein expression in mice leads to HCC, indicating direct oncogenesis.
    • Irregular regeneration is associated with a significantly increased risk of HCC.
    • Large cell dysplasia may be a marker rather than a direct pre-malignant lesion.
    • Steroidal contraception shows minimal increased HCC risk; tamoxifen demonstrated no benefit in a large trial.
    • Octreotide showed preliminary promise for advanced HCC survival and quality of life.
    • Interferon treatment is linked to reduced HCC risk, but requires randomized validation.

    Conclusions:

    • Hepatitis C can directly contribute to hepatocellular carcinoma development.
    • Identifying specific lesions and understanding risk factors are crucial for HCC prevention and management.
    • Further randomized controlled trials are essential to confirm the benefits of treatments like interferon and octreotide for HCC.